https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43081 Tue 13 Sep 2022 12:19:26 AEST ]]> Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30292 Sat 24 Mar 2018 07:33:34 AEDT ]]>